Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cells

Human Gene Therapy

Volumn 20, Issue 12, 2009, Pages 1703-1707

  Bielas, Jason H ^a,b   Schmitt, Michael W ^b   Icreverzi, Amalia ^a   Ericson, Nolan G ^a   Loeb, Lawrence A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; THYMIDYLATE SYNTHASE;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CYTOTOXICITY; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC VARIABILITY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NONHUMAN;

AMINO ACID SUBSTITUTION; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG RESISTANCE; FLOXURIDINE; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELLS; HUMANS; PROTEIN CONFORMATION; SUPPRESSION, GENETIC; THYMIDYLATE SYNTHASE; TRANSDUCTION, GENETIC;

EID: 74549114202     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.053     Document Type: Article

References (16)

1. Allay, J.A., Persons, D.A., Galipeau, J., Riberdy, J.M., Ashmun, R.A., Blakley, R.L., and Sorrentino, B.P. (1998). In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4, 1136-1143.
2. Banerjee, D., and Bertino, J.R. (2002). Myeloprotection with drug-resistance genes. Lancet Oncol. 3, 154-158.
3. Budak-Alpdogan, T., Banerjee, D., and Bertino, J.R. (2005). He-matopoietic stem cell gene therapy with drug resistance genes: An update. Cancer Gene Ther. 12, 849-863.
4. Carreras, C.W., and Santi, D.V. (1995). The catalytic mechanism and structure of thymidylate synthase. Annu. Rev. Biochem. 64, 721-762.
5. Encell, L.P., Landis, D.M., and Loeb, L.A. (1999). Improving enzymes for cancer gene therapy. Nat. Biotechnol. 17, 143-147.
6. Gerson, S.L. (2004). MGMT: Its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4, 296-307.
7. Kawate, H., Landis, D.M., and Loeb, L.A. (2002). Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J. Biol. Chem. 277, 36304-36311.
8. Klefstrom, J., Verschuren, E.W., and Evan, G. (2002). c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 277, 43224-43232.
9. Landis, D.M., Heindel, C.C., and Loeb, L.A. (2001). Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase. Cancer Res. 61, 666-672.
10. Noordhuis, P., Holwerda, U., van der Wilt, C.L., van Groenin-gen, C.J., Smid, K., Meijer, S., Pinedo, H.M., and Peters, G.J. (2004). 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colo-rectal cancers. Ann. Oncol. 15, 1025-1032.
11. Phan, J., Koli, S., Minor, W., Dunlap, R.B., Berger, S.H., and Lebioda, L. (2001). Human thymidylate synthase is in the closed conformation when complexed with dUMP and ralti-trexed, an antifolate drug. Biochemistry 40, 1897-1902.
12. Relling, M.V., and Dervieux, T. (2001). Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1, 99-108.
13. Salonga, D., Danenberg, K.D., Johnson, M., Metzger, R., Groshen, S., Tsaowei, D.D., Lenz, H.J., Leichman, C.G., Leichman, L., Diasio, R.B., and Danenberg, P.V. (2000). Col-orectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thy-midylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327.
14. Tong, Y., Liu-Chen, X., Ercikan-Abali, E.A., Capiaux, G.M., Zhao, S.C., Banerjee, D., and Bertino, J.R. (1998). Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate syn-thase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J. Biol. Chem. 273, 11611-11618.
15. van Kuilenburg, A.B., Meinsma, R., Zonnenberg, B.A., Zoete-kouw, L., Baas, F., Matsuda, K., Tamaki, N., and van Gennip, A.H. (2003). Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin. Cancer Res. 9, 4363-4367.
16. Yamada, Y., Hamaguchi, T., Goto, M., Muro, K., Matsumura, Y., Shimada, Y., Shirao, K., and Nagayama, S. (2003). Plasma concentrations of 5-fluorouracil and F-b-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br. J. Cancer 89, 816-820.